fevipiprant   Click here for help

GtoPdb Ligand ID: 8995

Synonyms: NVP-QAW039 | QAW039
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Fevipiprant is an orally available, selective antagonist of the prostanoid DP2 receptor (CRTh2) with anti-inflammatory action [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 97.64
Molecular weight 426.09
XLogP 3.73
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OC(=O)Cc1c(C)n(c2c1cccn2)Cc1ccc(cc1C(F)(F)F)S(=O)(=O)C
Isomeric SMILES OC(=O)Cc1c(C)n(c2c1cccn2)Cc1ccc(cc1C(F)(F)F)S(=O)(=O)C
InChI InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8H,9-10H2,1-2H3,(H,25,26)
InChI Key GFPPXZDRVCSVNR-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Phase 2I clinical trials evaluating QAW039 in asthma patients (NCT02555683 and NCT02563067) are registered with ClinicalTrials.gov.

Phase 2 trial results are published in [1] and report that fevipiprant is well tolerated and reduces eosinophilic airway inflammation in patients with persistent moderate-to-severe asthma resistant to inhaled corticosteroid treatment (i.e. patients maintaining raised sputum eosinophil counts whilst using corticosteroids).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Prostaglandin D2 (PGD2) is an established activator of the allergic inflammatory response. The DP2 receptor is notably expressed on T helper 2 (Th2) inflammatory cells. Antagonising PGD2-induced DP2 receptor activation is considered a valid therapeutic modality for treatment of asthma, allergic rhinitis and atopic dematitis.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02555683 Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. Phase 3 Interventional Novartis
NCT02563067 Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. Phase 3 Interventional Novartis